Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Grifols, S.A.

GRFSNASDAQ
Healthcare
Drug Manufacturers - General
$9.44
$0.04(0.43%)
U.S. Market opens in 12h 55m

Grifols, S.A. (GRFS) Stock Overview

Explore Grifols, S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap7.7B
P/E Ratio13.94
EPS (TTM)$0.65
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$9.43
3 Months$9.52
1 Year Target$10.25

GRFS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Grifols, S.A. (GRFS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 44.87, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $10.25.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 13.94 and a market capitalization of 7.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-3.51%
5-Day Change
-5.52%
1-Month Change
-1.63%
3-Month Change
7.98%
6-Month Change
-10.73%
Year-to-Date (YTD) Change
-1.84%
1-Year Change
22.07%
3-Year Change
-2.26%
5-Year Change
-43.63%
All-Time (Max) Change
37.009%

Contact Information

34 93 571 02 21
Avinguda de la Generalitat, 152, Barcelona, NaN, 08174

Company Facts

238,330 Employees
IPO DateJun 2, 2011
CountryES
Actively Trading

Frequently Asked Questions